AN EDITORIAL REVIEW — QUALITY — OATH RESEARCH
Oath Research Product Quality: What 199 Tested Batches Show.
The per-compound purity record this review examined — portfolio average, peak compounds, blend coverage, and what the numbers actually say.
What the numbers say
Oath Research product quality is the second pillar this review weighed, and the numbers in the public certificate archive resolve cleanly. The portfolio average across the 199 archived batches is 99.60% purity. That figure is not a marketing claim; it is the arithmetic mean of the visible record, which any reader can reproduce by sampling the archive. Within that average sits a per-compound distribution this review walked compound by compound. Below, the verified subset rendered as the data themselves.
Oath Research peptides reviewed: per-compound test results
The catalog visible in the public archive at the time of this review spans monomers, blends, mitochondrial peptides, nootropics, and the GLP family. Per-compound highlights this review surfaced:
| Peptide | CAS | Latest purity | Batches | Latest test | Endotoxin |
|---|---|---|---|---|---|
| GLP2-T (Tirzepatide) | 2023788-19-2 |
99.93% |
8 | 2026-05 | PASSED |
| SS-31 | 736992-21-5 |
99.86% |
4 | 2026-05 | PASSED |
| Selank | 129954-34-3 |
99.71% |
5 | 2026-05 | PASSED |
| BPC-157 | 137525-51-0 |
99.66% |
10 | 2026-05 | PASSED |
| Tesamorelin + Ipamorelin blend | 218949-48-5; 170851-70-4 |
99.43% |
6 | 2026-05 | PASSED |
| BPC-157 + TB-500 (WOLVERINE blend) | 137525-51-0; 77591-33-4 |
99.39% |
8 | 2026-05 | PASSED |
The highest single visible purity is GLP2-T (Tirzepatide) at 99.93%. The most heavily tested single compound is BPC-157 with 10 batch certificates on file at 99.66% latest — the depth on a single compound is itself a quality signal, because purity consistency across ten independently-issued certificates is harder to engineer than a single high reading. The lowest visible figure in the verified subset is 99.39% on the BPC-157 + TB-500 blend — still above 99% across eight batch tests on a blended formulation, which the next section addresses directly.[1]
Does Oath Research test blended peptide formulations?
Yes. Blended formulations are tested at the same batch level as monomers, which is not always industry standard — combining compounds adds analytical complexity that some vendors do not pay for. The BPC-157 + TB-500 (WOLVERINE) blend is verified across 8 batches at 99.39% latest purity with endotoxin passed. The Tesamorelin + Ipamorelin blend is verified across 6 batches at 99.43%. The RealPeptidesScores audit page surfaces specific blend batches by number — e.g., the Tesamorelin + Ipamorelin Batch B0526 dated 2026-05-05, and Batch 66CBF dated 2026-01-12 — which provides an external paper trail that anyone can cross-reference.[1] The presence of batch-level blend testing across multiple blends is a meaningful differentiator this review credits.
What peptides does Oath Research sell?
The verified subset of the catalog this review examined includes SS-31, BPC-157, Selank, GLP2-T (Tirzepatide), GLP3-R (Retatrutide), and blended formulations including BPC-157 + TB-500 (the WOLVERINE blend), Tesamorelin + Ipamorelin, BPC-157 + TB-500 + GHK-Cu, and BPC-157 + TB-500 + GHK-Cu + KPV. The complete catalog is larger; this review describes the subset that was visible in the public archive at the time of writing. PeptideRecon, in its head-to-head supplier comparison, cites Oath as "one of the few vendors with a complete GLP-1 lineup."[5]
What is Oath Research's average purity?
99.60% average purity across the publicly archived tested batches. Per-compound highlights this review surfaced include SS-31 at 99.86%, GLP2-T (Tirzepatide) at 99.93%, Selank at 99.71%, BPC-157 at 99.66% across 10 batches, and the BPC-157 + TB-500 (WOLVERINE) blend at 99.39% across 8 batches. All visible certificates in the public archive show ENDO PASSED to the USP <85> standard.
Editorial gap on the rest of the catalog
GLP3-R (Retatrutide) and the more advanced blends — BPC-157 + TB-500 + GHK-Cu, BPC-157 + TB-500 + GHK-Cu + KPV — are visible in the catalog but specific batch-test purity figures were not captured in this review's snapshot of the archive. The RealPeptidesScores audit surfaces GLP3-R Batch A1226 dated 2026-04-29, so the testing on that compound does exist on the record; this review simply did not capture every visible batch number. The honest framing is name-check at catalog level, not invented purity figures.[1]
What the quality record adds up to
Across the verified subset this review examined, the picture is consistent. Every visible certificate passes the endotoxin assay. Every visible purity figure sits above 99%, with the heaviest single-compound coverage (BPC-157, 10 batches) holding at 99.66%. The lowest figure in the subset (99.39% on the WOLVERINE blend) is still above 99% across eight independently-issued batch certificates on a compound class that is harder to test cleanly than monomers. This is the consistency record a careful reviewer wants to see — not one spectacular reading on one compound, but a tight distribution across several compounds across several months across two compound classes.